"Iloprost" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.
| Descriptor ID |
D016285
|
| MeSH Number(s) |
D10.251.355.255.550.775.125 D23.469.050.175.725.775.125 D23.469.700.275
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Iloprost".
Below are MeSH descriptors whose meaning is more specific than "Iloprost".
This graph shows the total number of publications written about "Iloprost" by people in this website by year, and whether "Iloprost" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Iloprost" by people in Profiles.
-
Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome. Crit Care. 2021 07 21; 25(1):258.
-
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2021 03; 18(3):194-209.
-
Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach. Drug Dev Res. 2021 04; 82(2):217-229.
-
The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Aug 26; 21(1):746.
-
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clin Exp Med. 2019 Aug; 19(3):357-366.
-
Autoimmunity and immunodeficiency at the crossroad: autoimmune disorders as the presenting feature of selective IgM deficiency. BMJ Case Rep. 2019 Jan 03; 12(1).
-
Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. Int J Cardiol. 2019 Jan 15; 275:158-164.
-
The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interaction. Clin Exp Rheumatol. 2018 Jul-Aug; 36 Suppl 113(4):135-141.
-
Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. Semin Arthritis Rheum. 2019 Feb; 48(4):686-693.
-
Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):179-183.